← Prism News

STAT+: Abivax seeks to ease safety concerns with new data, boosting shares

Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.

Left 0% Center 100% Right 0% · 1 sources

All sources

Open full story with side-by-side comparison →

Prism News is a free news aggregator that breaks every story into Left, Center and Right perspectives — see what each side covers, what they ignore, and how the same event gets framed differently.